These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25023576)

  • 41. Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
    Hetzel DJ; Dent J; Reed WD; Narielvala FM; Mackinnon M; McCarthy JH; Mitchell B; Beveridge BR; Laurence BH; Gibson GG
    Gastroenterology; 1988 Oct; 95(4):903-12. PubMed ID: 3044912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
    Dupas JL; Houcke P; Samoyeau R;
    Gastroenterol Clin Biol; 2001 Mar; 25(3):245-50. PubMed ID: 11395670
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abdominal obesity is an independent risk factor for erosive esophagitis in a Korean population.
    Kang MS; Park DI; Oh SY; Yoo TW; Ryu SH; Park JH; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1656-61. PubMed ID: 17845694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
    Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Omeprazole for severe reflux esophagitis in children.
    De Giacomo C; Bawa P; Franceschi M; Luinetti O; Fiocca R
    J Pediatr Gastroenterol Nutr; 1997 May; 24(5):528-32. PubMed ID: 9161946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1165-71. PubMed ID: 19298581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy.
    Lee YC; Wang HP; Chiu HM; Liao SC; Huang SP; Lai YP; Wu MS; Chen MF; Lin JT
    J Gastroenterol Hepatol; 2006 May; 21(5):798-804. PubMed ID: 16704526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients.
    Rezailashkajani M; Roshandel D; Shafaee S; Zali MR
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):499-506. PubMed ID: 17489061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. The Central Finland Endoscopy Study Group.
    Voutilainen M; Färkkilä M; Mecklin JP; Juhola M; Sipponen P
    Am J Gastroenterol; 1999 Nov; 94(11):3175-80. PubMed ID: 10566710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endoscopic esophagitis is more severe in gastroesophageal reflux patients with a positive family history.
    Tsibouris P; Moussia M; Kalantzis C; Apostolopoulos P; Alexandrakis G; Lapas C; Kalantzis N
    J Clin Gastroenterol; 2012 Mar; 46(3):201-8. PubMed ID: 22138842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Yokota K; Oguma K; Okada H; Yamamoto K
    J Gastroenterol Hepatol; 2009 Jan; 24(1):107-13. PubMed ID: 18823429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of leukotriene receptor antagonist for erosive esophagitis: a preliminary retrospective comparative study.
    Lee H; Park JC; Shin SK; Lee SK; Lee YC
    Dis Esophagus; 2012; 25(7):595-9. PubMed ID: 22211520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
    Vasil'ev IuV; Li IA
    Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endoscopic evaluation of gastro-esophageal reflux disease.
    Armstrong D
    Yale J Biol Med; 1999; 72(2-3):93-100. PubMed ID: 10780570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
    Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Reflux esophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Preliminary report].
    Córdova-Villalobos JA; Ramírez-Barba EJ; Ramírez-Covarrubias JC
    Rev Gastroenterol Mex; 1996; 61(4):306-9. PubMed ID: 9072780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.